Table 3.

Adverse events among women and live-born infants

	Efavirenz n (%)	Lopinavir/ritonavir n (%)	p
Pregnant women	N = 195	N = 194
Any grade 1 or 2 adverse event	177 (90.8)	182 (93.8)	0.26
Diarrhea	18 (9.2)	43 (22.2)	<0.001
Nausea/vomiting	29 (14.9)	53 (27.3)	0.003
Any grade 3 or 4 adverse event	12 (6.2)	8 (4.1)	0.36
Anemia	5 (2.6)	3 (1.6)	0.72
Neutropenia	3 (1.5)	2 (1.0)	1.00
Non-obstetrical hospitalization	7 (3.6)	8 (4.1)	0.78
Death	0	0	N/A
Postpartum women	N = 187	N = 190
Any grade 1 or 2 adverse event	179 (95.7)	187 (98.4)	0.12
Diarrhea	54 (28.9)	74 (39.0)	0.04
Nausea/vomiting	20 (10.7)	34 (17.9)	<0.05
Any grade 3 or 4 adverse event	32 (17.1)	36 (19.0)	0.64
Anemia	4 (2.1)	6 (3.2)	0.75
Neutropenia	24 (12.8)	27 (14.2)	0.70
Non-obstetrical hospitalization	5 (2.7)	1 (0.5)	0.12
Death	0	1	1.00
Live-born infants	N = 183	N = 191
Any grade 1 or 2 adverse event	176 (96.2)	179 (93.7)	0.28
Any grade 3 or 4 adverse event	40 (21.9)	51 (26.7)	0.28
Anemia	19 (10.4)	32 (16.8)	0.07
Neutropenia	17 (9.3)	14 (7.3)	0.49
Hospitalization	5 (2.7)	6 (3.1)	0.81
Death	5 (2.7)	12 (6.3)	0.10